 |
 |
If you find this site useful or just support what I'm doing, I'd really appreciate if you could donate. To cover server costs and for the hundreds of hours I've put into making this happen.
|
 |
If you spot content on this site that is genuinely illegal or actually puts someone in real danger, contact [email protected]. We have multiple agents reviewing tickets 24/7. Note that we try to maintain as much transparency as possible, both about ourselves and of the actions of Wikipedians. For example, if we removed a live link to CSAM content that was posted by a Wikipedia admin, we would replace it a placeholder like "<link to CSAM that was posted by Demiurge1000 redacted by Undersight>". Note that "I don't like it" is NOT a valid removal reason. If instead you are a Wikipedophile trying to get all the dark secrets of Wikipedia censored, please follow this guide instead.
If you would like to contact the owner of this about something else (e.g. press inquires, feature requests, bug reports), e-mail [email protected] or [email protected].
|
Revision 166807086 of "Benutzer:Verzettelung/Teva Pharmaceutical Industries" on dewiki{{Use mdy dates|date=March 2015}}
{{Infobox company
| name = Teva Pharmaceutical Industries Ltd.<br />{{Hebrew|טבע תעשיות פרמצבטיות בע"מ}}
| logo = [[Image:Teva logo.svg|250px]]
| type = [[Public company|Public]]
| traded_as = {{NYSE|TEVA}}<br>{{TASE|TEVA}}
| founder = Chaim Salomon<br />Moshe Levin<br />Yitschak Elstein
| key_people = {{unbulleted list|Yitzhak Peterburg, Interim President & CEO|Sol Barer, Chairman|Eyal Desheh, Chief Financial Officer}}
| industry = [[Pharmaceutical]]
| products = Pharmaceuticals
| revenue = {{profit}}$20.3 billion [[United States dollar|USD]] ([[fiscal year|FY]] 2014)
| operating_income = {{profit}}$3.951 billion [[United States dollar|USD]] ([[fiscal year|FY]] 2014)
| net_income = {{profit}}$3.055 billion [[United States dollar|USD]] ([[fiscal year|FY]] 2014)
| num_employees = 43,000 (2014)
| homepage = {{url|www.teva.co.il/}}<br>{{url|www.tevapharm.com/}}
| foundation = {{start date and age|1901}}
| location_city = [[Petah Tikva]]
| location_country = [[Israel]]
| generic buprenorphine 2 mg 8 mg sublingual tablets
|
|
}}
'''Teva Pharmaceutical Industries Ltd.''' ({{lang-he-n|טבע תעשיות פרמצבטיות בע"מ}}) is an [[Israeli]] [[multinational corporation|multinational]] [[pharmaceutical company]] headquartered in [[Petah Tikva]], [[Israel]].<ref>{{Cite web|url=https://www.israelbizreg.com/teva-pharmaceutical-industries-limited|title=TEVA PHARMACEUTICAL INDUSTRIES LIMITED {{!}} Israel Company Reports - Search Israeli Companies|website=www.israelbizreg.com|access-date=2016-10-19}}</ref> It specializes primarily in [[generic drug]]s, but other business interests include [[active pharmaceutical ingredient]]s and, to a lesser extent, proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world<ref name=hollisfiercepharma2010/> and one of the 15 largest pharmaceutical companies worldwide.<ref name=biojerusalem/> Teva's facilities are located in Israel, North America, Europe, and South America. Teva shares trade on both the [[New York Stock Exchange]] (via [[American depositary receipt|ADRs]]) and the [[Tel Aviv Stock Exchange]]. The company is a member of the [[Pharmaceutical Research and Manufacturers of America]] (PhRMA).<ref>http://www.fiercepharma.com/pharma/teva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals</ref>
==History==
[[Image:Assia.jpeg|thumb|150px|Worker at Assia plant in the 1930s]]
[[File:TevaFactoryJerusalem9.jpg|thumb|Teva plant, [[Har Hotzvim]], Jerusalem]]
[[File:TevaCanada2.jpg|thumb|Teva in Markham, Ontario]]
Teva's earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in [[Palestine (region)|Palestine]] that was founded in 1901, and used camels to make deliveries.<ref>https://books.google.co.il/books?id=L0gjBAAAQBAJ&pg=PA173&lpg=PA173&dq=teva+delivering+drugs+on+camel&source=bl&ots=2iE8nYsw1l&sig=MLEMnGt_jt9rs5YN21bAreHkF-Y&hl=en&sa=X&ved=0ahUKEwiWrtCfq-zSAhUqKcAKHTuJCFYQ6AEIMzAE#v=onepage&q=teva%20delivering%20drugs%20on%20camel&f=false</ref> During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva ("Nature" in Hebrew), Assia, and Zori. In 1951, Teva raised capital through the newly founded [[Tel-Aviv Stock Exchange]] after the formation of the new country, Israel.
In 1964, Assia and Zori merged and acquired a controlling interest in Teva. In 1976, these three companies merged into the modern-day Teva Pharmaceutical Industries Ltd. In 1980, Teva continued to follow its vision of becoming one of the world's biggest pharmaceutical companies by acquiring Ikapharm, then Israel's second largest drug manufacturer.<ref name="21st Century — Global Leadership"/>
In 1982, Teva was granted approval by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) for its [[Kfar Saba]] manufacturing plant, an essential milestone for marketing pharmaceuticals in the USA.
In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in [[Har Hotzvim]], a technology park in [[Jerusalem]]. The plant received FDA approval in early 2007.<ref name=singernyt2010/> Teva entered the Japanese market in 2005, and in 2008 established a generics [[joint venture]] with Kowa.<ref name=KGPTM2011/>
In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. Teva acquired its U.S. rival [[Ivax Corporation]] in January 2006,<ref>Jennifer Bayot for the New York Times. July 26, 2005 [https://www.nytimes.com/2005/07/26/business/teva-to-acquire-ivax-another-maker-of-generic-drugs.html?_r=0 Teva to Acquire Ivax, Another Maker of Generic Drugs]</ref><ref>Teva Press Release, 2006. [http://tevapharm.com/news/teva_completes_acquisition_of_ivax_01_06.aspx Teva Completes Acquisition of Ivax]</ref> Barr in 2007 and Ratiopharm in 2010.
In 2010, Teva announced that it would build its main distribution center for the Americas in Philadelphia, PA, and was considering opening its US headquarters in the area.<ref name=singernyt2010/>
In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% by 6,774.<ref name="Teva employees gain $222m on options"/> In March 2010, Teva acquired German-based company [[Ratiopharm]] in a deal worth almost $5 billion, significantly expanding its European coverage.<ref name="Yahoo deadlink"/><ref name="Teva to Acquire Generics Firm"/><ref name="Teva to acquire Ratiopharm in deal valued near $5 billion"/> In October 2010, Teva entered a licensing agreement with [[BioTime]] to develop and market BioTime's OpRegen for the treatment of [[age-related macular degeneration]],<ref>{{cite web |title= Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd. |url= http://www.businesswire.com/news/home/20101010005096/en/Cell-Cure-Neurosciences-Ltd.-Subsidiary-BioTime-Hadasit}}</ref> an effort that in 2013 received $1.5 billion in funding from Israel's [[Office of the Chief Scientist (Israel)|Office of the Chief Scientist]].<ref>{{cite web |title= BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist |url= http://www.businesswire.com/news/home/20130513005575/en/BioTime%E2%80%99s-Subsidiary-Cell-Cure-Neurosciences-Ltd.-Awarded}}</ref> In May 2011 Teva announced it would purchase [[Cephalon]] for US$6.8 billion, to help expand its presence in the proprietary pharmaceuticals sector.
[[Teva Active Pharmaceutical Ingredients (TAPI)]] operates within Teva as a stand-alone business unit. As well as providing for Teva's own needs, the TAPI division is an active competitor in world markets. In 2009, TAPI's sales to third parties totaled $565 million, and in 2010 sales rose by 13% to a total of $641 million.
==Corporate governance==
{| class="wikitable"
|-
! Chief Executive Officer !! Period of office !! Notes
|-
| [[Eli Hurvitz]] || 1976 to 2002 || CEO & Chairman of the board until his death in 2011.<ref name=reuters/><ref name=coren2008/>
|-
| [[Israel Makov]] || 2002 to 2007|| <ref name=tevanr2002/><ref name=ynet2006/>
|-
| [[:simple:Shlomo Yanai|Shlomo Yanai]] || March 2007 to May 2012 || Announced his resignation at the beginning of 2012.<ref name=yanairesign/>
|-
| [[Jeremy Levin]] || May 2012 to October 2013|| <ref name=levinresig/>
|-
| [[Eyal Desheh]] || October 2013 to January 2014|| Interim CEO
|-
| [[Erez Vigodman]] || January 2014 to February 2017 || Desheh returned to previous position of [[chief financial officer]].<ref name=bloomberg2jan2012/><ref name=reuters20140109/><ref name=geneng20140215/> Vigodman served as the CEO of [[Makhteshim Agan]] until joining Teva, and was President and CEO of [[Strauss (company)|Strauss Group]] prior to this.<ref name=geneng20140215/> From 2014, [[Michael R. Hayden|Michael Hayden]] served as Teva's [[Chief science officer|chief scientific officer]] and president of the company's global research and development.<ref name="george2014" />
|-
|Yitzhak Peterburg
|February 2017 to present day
|Peterburg held the position of Chairman since 2015. He was appointed as Interim President and CEO in 2017 succeeding Erez Vigodman. Since Israeli law does not permit the same individual to serve as CEO and Chairman, Sol J Barer took over as the Chairman of the board in February 2017.<ref>{{Cite web|url=https://teva-actavis.newsweaver.com/icfiles/2/77531/173109/163545/e83b65116c42e31302eb3c08/teva%20management%20change%20prfinal_4.pdf|title=Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman|last=|first=|date=|website=|dead-url=|access-date=}}</ref>
|}
==Mergers and acquisitions==
===1980 to 1999===
In 1980, Teva acquired [[Plantex]].<ref>{{cite web|url=http://www.tapi.com/About-US/WorldWide/Pages/PlantexLtd.aspx|title=Teva — Plantex Limited|work=tapi.com}}</ref>
===2000 to 2009===
In 2000 Teva acquired Canada-based [[Novopharm]].<ref>{{cite web|url=http://www.newswire.ca/en/story/626423/novopharm-limited-becomes-teva-canada-limited|title=TEVA NOVOPHARM — Novopharm Limited becomes Teva Canada Limited|work=newswire.ca}}</ref> In January 2006, Teva said it had completed the acquisition of [[IVAX Corporation]] for around $7.4 billion.<ref>http://www.tevapharm.com/media/news/pages/2006/1557278.aspx</ref> The acquisition price was $7.4 billion.<ref>{{cite news|url=http://usatoday30.usatoday.com/money/industries/health/drugs/2005-07-25-teva-ivax_x.htm|title=USATODAY.com — Teva Pharmaceuticals to buy Ivax in $7.4 billion deal|work=usatoday.com | first1=Julie|last1=Schmit|date=July 26, 2005}}</ref> On December 23, 2008, Teva acquired [[Barr Pharmaceuticals]] for $7.5 billion, making Barr and [[Pliva]] (which Barr bought earlier) part of Teva.<ref name="Teva Completes Acquisition of Barr"/>
===2010 onwards===
On March 18, 2010, Teva said it planned to acquire German generic [[Ratiopharm]] for US$5 billion. The deal was completed in August 2010.<ref name=singernyt2010/> In May 2011, Teva bought [[Cephalon]] for US$6.8 billion.<ref name="Teva to Buy Cephalon for $6.8 Billion" /> The same month, Teva announced the ¥40 billion purchase of a majority stake in Japanese generic drug company [[Taiyo Pharmaceutical Industry]], a move to secure a Japan-local production facility.<ref name=KGPTM2011/> Teva completed the $934 million acquisition on July 2011.<ref>[http://www.globes.co.il/serveen/globes/docview.asp?did=1000664169&fid=1725 Teva completes $934m Taiyo acquisition], Globes, 14 July 11</ref> In June 2013 Teva acquired US firm [[MicroDose]] for $40 million with as much as $125 million being paid in regulatory and developmental milestones <ref>{{cite news|url=https://www.bloomberg.com/news/2013-06-17/teva-adds-microdose-to-respiratory-business-in-165-million-deal.html|title=Teva Adds MicroDose to Respiratory Business in $165 Million Deal|author=David Wainer|work=Bloomberg.com|date=June 17, 2013}}</ref> In January 2014, Teva acquired [[NuPathe]], after outbidding [[Endo Health Solutions|Endo]], for $144 million.<ref name=geneng20140215p10/> In June 2014, Teva acquired [[Labrys Biologics]] for up to $825 million,<ref name=genengnews2014>{{cite news
|title=Teva Buys Labrys, Growing Pain Franchise in Up to $825M Deal |author=Staff |work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]] |date=June 3, 2014 |url=http://www.genengnews.com/gen-news-highlights/teva-buys-labrys-growing-pain-franchise-in-up-to-825m-deal/81249936/ |accessdate=July 21, 2014 }}</ref> the aim being to strengthen the company's migraine pipeline through addition of LBR-101, an anti-[[Calcitonin gene-related peptide|CGRP]] [[monoclonal antibody therapeutic]].<ref name=george2014>{{cite news
|last1=George |first1=John |title=Teva completes deal for second migraine-treatment developer |url=http://www.bizjournals.com/philadelphia/blog/health-care/2014/07/teva-completes-deal-for-second-migrainetreatment.html |accessdate=July 21, 2014 |work=[[Phila. Bus. J.|Philadelphia Business Journal]] |date=July 21, 2014 }}</ref> In March 2015, Teva acquired [[Auspex Pharmaceuticals]] for $3.5 billion growing its CNS portfolio.<ref>{{cite news|url=http://www.genengnews.com/gen-news-highlights/teva-to-acquire-auspex-for-3-5b-growing-cns-portfolio/81251086/ |author=Staff |date=March 30, 2015 |accessdate=April 21, 2015 |title=Teva to Acquire Auspex for $3.5B, Growing CNS Portfolio |department=GEN News Highlights |work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]] }}</ref> In April, Teva offered to acquire [[Mylan]] for $40 billion,<ref>{{cite news|url=http://www.genengnews.com/gen-news-highlights/teva-offers-to-buy-mylan-for-40b/81251178/ |title=Teva Offers to Buy Mylan for $40B |date=April 21, 2015 |author=Staff |accessdate=April 21, 2015 |work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]] |department=GEN News Highlights }}</ref> only a fortnight after Mylan offered to buy [[Perrigo]] for $29 billion.<ref>{{cite news
|url=http://www.genengnews.com/gen-news-highlights/mylan-offers-28-9b-for-perrigo/81251129/ |author=Staff |title=Mylan Offers $28.9B for Perrigo |work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]] |department=GEN News Highlights |date=April 8, 2015 |accessdate=April 21, 2015 }}</ref> Teva's offer for Mylan was contingent on Mylan abandoning its pursuit of Perrigo.<ref>{{cite news
|author=Associated Press |title=Teva Offers to Buy Mylan in $40.1B Cash-And-Stock Deal |date=April 21, 2015 |accessdate=April 21, 2015 |work=[[Pharma. Process.|Pharmaceutical Processing]] |url=http://www.pharmpro.com/news/2015/04/teva-offers-buy-mylan-401b-cash-and-stock-deal?et_cid=4527542&et_rid=280926499&location=top }}</ref> Mylan stated in June 2015 that Teva’s disclosure that it had a 1.35 percent stake in Mylan violated [[US]] anti-trust rules.<ref>{{cite news|author=Anjali Rao Koppala |url=http://www.reuters.com/article/2015/06/01/us-mylan-m-a-teva-pharm-ind-idUSKBN0OH3H520150601 |title=Mylan says Teva's stake buy violates U.S. anti-trust rules |publisher=Reuters |date=1 June 2015 |accessdate=2 June 2015}}</ref> In October, the company acquired Mexico-based Representaciones e Investigaciones Medicas (Rimsa) for around $2.3 billion.<ref>{{cite web|url=http://www.fiercepharma.com/story/teva-beefs-emerging-markets-23b-rimsa-buyout/2015-10-01|title=Teva beefs up in emerging markets with $2.3B Rimsa buyout - FiercePharma|publisher=}}</ref> In the same month Teva acquired [[Gecko Health Innovations]].<ref>{{cite web|url=http://www.fiercepharmamarketing.com/story/teva-snaps-gecko-and-its-smart-inhaler-pump-respiratory-meds/2015-10-05|title=Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds - FiercePharma|publisher=}}</ref>
In November 2015, the company announced it would collaborate with [[Heptares Therapeutics]] with its work on small-molecule [[calcitonin]] gene-related peptide [[antagonists]] for migraine treatment, with the deal generating up to $410 million.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/teva-heptares-launch-up-to-410m-migraine-alliance/81252024/|title=Teva, Heptares Launch Up-to-$410M+ Migraine Alliance - GEN News Highlights - GEN|publisher=}}</ref>
====Actavis Generics====
{{Main article|Actavis}}
In July 2015, Allergan agreed to sell its [[generic drug]] business (Actavis Generics<ref name="fiercepharma.com">{{cite web|url=http://www.fiercepharma.com/pharma/analyst-cuts-allergan-generics-sales-estimates-as-teva-deal-close-nears|title=Analyst cuts Allergan generics sales estimates as Teva deal close nears - FiercePharma|publisher=}}</ref>) to Teva for $40.5 billion<ref>{{cite news|url=https://www.bloomberg.com/news/videos/2015-07-27/teva-to-buy-allergan-s-generic-drug-unit|title=Teva to Buy Allergan's Generic Drug Unit|date=July 27, 2015|work=Bloomberg.com}}</ref><ref>{{cite news|url=https://www.bloomberg.com/news/articles/2015-07-27/teva-ceo-sees-more-deals-coming-after-40-5b-allergan-purchase|title=Teva CEO: $40.5 Billion Allergan Deal is Just the Beginning - Bloomberg Business|author=Cynthia Koons|date=July 27, 2015|work=Bloomberg.com}}</ref><ref>{{cite news|url=https://www.bloomberg.com/news/videos/2015-07-27/teva-purchasing-allergan-s-generics-unit-in-40-5b-deal|title=Teva Purchasing Allergan's Generics Unit in $40.5B Deal|date=July 27, 2015|work=Bloomberg.com}}</ref> ($33.75 billion in cash and $6.75 billion worth of shares).<ref>{{cite news|url=https://www.bloomberg.com/news/articles/2015-07-27/teva-snaps-up-allergan-s-generics-arm-dumping-mylan|title=Teva Snaps Up Allergan’s Generics Arm, Dumping Mylan|author=Chitra Somayaji|date=July 27, 2015|work=Bloomberg.com}}</ref> As a result, Teva dropped its pursuit of [[Mylan]]. In order for the deal to gain regulatory approval, Teva sold off a number of assets, including a portfolio of five generic drugs to [[Sagent Pharmaceuticals]] for $40 million, as well as a further eight medicines to [[Dr. Reddy's Laboratories|Dr. Reddy’s]] in a $350 million deal.<ref name="fiercepharma.com"/> Teva also sold a further 15 marketed generics, as well as three others which were close to market, for $586 million to [[Impax Laboratories]].<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/impax-buys-generic-product-portfolio-from-teva-allergan-for-586m/81252854/|title=Impax Buys Generic Product Portfolio from Teva, Allergan for $586M - GEN News Highlights - GEN|publisher=}}</ref><ref>{{cite web|url=http://www.fiercepharma.com/pharma/teva-sells-cast-offs-to-impax-for-586m-as-clock-ticks-allergan-deal|title=Teva sells castoffs to Impax for $586M as clock ticks on Allergan deal - FiercePharma|publisher=}}</ref> In July, Teva sold off a further 42 products to Australian generics company, [[Mayne Pharma]], for $652 million; the deal moved Mayne up 50 spots, into the top-25 companies of US generic companies.<ref>{{cite web|url=http://www.fiercepharma.com/pharma/mayne-scoops-up-42-meds-from-teva-allergan-652m-deal|title=Mayne vaults ahead in U.S. with $652M deal for Teva/Allergan meds - FiercePharma|publisher=}}</ref> As part of the deal Teva will seek to raise $20 to $25 billion<ref>{{cite web|url=http://www.fiercepharma.com/pharma/teva-looks-for-20b-plus-from-bond-sale-to-finance-allergan-deal|title=Teva looks for $20B-plus from bond sale to finance Allergan deal - FiercePharma|publisher=}}</ref> through a bond sale.<ref>{{cite web|url=https://www.sec.gov/Archives/edgar/data/818686/000119312516647185/d220417d6k.htm|title=Form 6-K|publisher=}}</ref>
After completing the $39 billion acquisition of Actavis Generics, Teva announced another, smaller, deal with Allergan, agreeing to acquire its generic distribution business [[Anda (company)|Anda]] for $500 million.<ref>http://www.genengnews.com/gen-news-highlights/after-completing-39b-acquisition-teva-does-another-generics-deal-with-allergan/81253042/</ref>
===Acquisition history===
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
{{clade | style=font-size:90%;line-height:110% |thickness=0
|label1=Teva Pharmaceutical Industries<span style="font-size:100%;"><!-- LEVEL 1-->
|1= {{clade
|label1=
|1=Gecko Health Innovations<br/><small>(Acq 2015)</small>
|2= {{clade
|label1=
|1=Rimsa<br/><small>(Acq 2015)</small>
|3= {{clade
|label1=
|1=[[Actavis|Actavis Generics]]<br/><small>(Generic drug div [[Allergan, plc]], Acq 2015)</small>
|4= {{clade
|label1=
|1=Auspex Pharmaceuticals<br/><small>(Acq 2014)</small>
|5= {{clade
|label1=
|1=Labrys Biologics<br/><small>(Acq 2014)</small>
|6= {{clade
|label1=
|1=NuPathe after<br/><small>(Acq 2014)</small>
|7= {{clade
|label1=
|1=MicroDose<br/><small>(Acq 2013)</small>
|8= {{clade
|label1=
|1=Taiyo Pharmaceutical Industry <br/><small>(Acq 2011)</small>
|9= {{clade
|label1=[[Cephalon]]<br/><small>(Acq 2011)</small>
|1= {{clade
|label1=
|1=Arana Therapeutics<br/><small>(Acq 2009)</small>
|2= {{clade
|label1=
|1=ChemGenex Pharmaceuticals<br/><small>(Acq 2011)</small>
}} }}
|10= {{clade
|label1=
|1=[[Ratiopharm]]<br/><small>(Acq 2010)</small>
|11= {{clade
|label1=
|1=[[Barr Pharmaceuticals]] <br/><small>(Acq 2008)</small>
|12= {{clade
|label1=
|1=IVAX Corporation<br/><small>(Acq 2006)</small>
|13= {{clade
|label1=
|1=Novopharm<br/><small>(Acq 2000)</small>
|14= {{clade
|label1=
|1=Plantex<br/><small>(Acq 1980)</small>
|15= {{clade
|label1=
|1=Ikapharm<br/><small>(Acq 1980)</small>
|16= {{clade
|label2=
|1=Salomon, Levin, and Elstein Ltd<br/><small>(Merged 1976 to form Teva Pharmaceutical Industries Ltd)</small>
|label3=
|2=Assia<br/><small>(Merged 1976 to form Teva Pharmaceutical Industries Ltd)</small>
|label4=
|3=Zori<br/><small>(Merged 1976 to form Teva Pharmaceutical Industries Ltd)</small>
|17= {{clade
|label5=
|1=[[Glaxo]]<br/><small>(Acq 1914)</small>
|2=[[Margarine Unie]]<br/><small>(Acq 1924)</small>
|3=[[Allen & Hanburys]]<br/><small>(Merged 1976 to form Teva Pharmaceutical Industries Ltd)</small>
}} }} }} }} }} }} }} }} }} }} }} }} }} }} }} }} }} }} {{hidden end}}
==Research and development==
[[File:Copaxone.jpg|thumb|250px|[[Glatiramer acetate|Copaxone]], a Teva patented drug]]
Teva holds patents on multiple drugs, including: [[Glatiramer acetate|Copaxone]], a specialty drug<ref name="tevapharm" /> (for the treatment of [[multiple sclerosis]]), now the world's best selling MS drug,<ref name="reuters_2015_07_30">{{cite web | url=http://www.reuters.com/article/2015/07/30/teva-pharm-ind-results-idUSL5N10A3VA20150730 | title=Teva's MS drug Copaxone has strong second-quarter sales | work=Reuters | date=July 2015 | accessdate=16 October 2015 | location=Jerusalem, Israel}}</ref> and [[Rasagiline|Azilect]] (sold as Agilect in some countries) for treatment of [[Parkinson's disease]]. By July 2015 Copaxone held a "31.2 percent shares of total MS prescriptions in the United States."<ref name="reuters_2015_07_30" /> Teva's new 40 mg version of Copaxone taken three times a week "accounted for 68.5 percent of total Copaxone prescriptions in the United States."<ref name="reuters_2015_07_30" /> Copaxone accounts for about fifty percent of "Teva's profit and 20 percent of revenue."<ref name="reuters_2015_07_30" /> Competitors' Glatopa, 20 mg version of Copaxone, is taken once a day.<ref name="reuters_2015_07_30" />
In June 2006, Teva received from the FDA a 180-day exclusivity period to sell [[simvastatin]] (Zocor) in the U.S. as a [[generic drug]] in all strengths except 80 mg. Teva presently{{When|date=March 2010}} competes with the maker of brand-name Zocor, [[Merck & Co.]]; [[Ranbaxy Laboratories]], which has 180-day exclusivity for the 80 mg strength; and [[Dr. Reddy's Laboratories]], whose authorized generic version (licensed by Merck) is exempt from exclusivity.
In June 2010, the company announced it would discontinue its production of [[propofol]], a major sedative estimated to be used in 75% of all US anesthetic procedures.<ref name="Teva won't make more of powerful sedative"/>
In March 2015 Teva sold four anti-cancer compounds to [[Ignyta Inc.]] for $41.6 million. As part of the deal Teva sold the following compounds which were then renamed:<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/ignyta-buys-four-cancer-compounds-from-teva/81251046/|title=GEN — News Highlights:Ignyta Buys Four Cancer Compounds from Teva|work=GEN}}</ref>
*[[CEP-32496]] (renamed RXDX-105) a small molecule inhibitor of [[BRAF (gene)|BRAF]], [[Epidermal growth factor receptor|EGFR]] and [[RET proto-oncogene|RET]], now in Phase I/II trials
*[[CEP-40783]] (renamed RXDX-106) a small molecule inhibitor of [[AXL receptor tyrosine kinase|AXL]] and [[c-Met]] in preclinical development
*[[CEP-40125]] (renamed RXDX-107) a nanoformulation of a modified [[bendamustine]] with potenital activity in solid tumours. Bendamustine Rapid Infusion as therapy for CLL and NHL is part of Teva's [[specialty drugs]] pipeline.<ref name="tevapharm">{{cite web | url=http://www.tevapharm.com/research_development/rd_focus/pipeline/ | title=Our Specialty Pipeline | work=Teva Pharmaceutical Industries | date=nd | accessdate=16 October 2015}}</ref>
*[[TEV-44229]] (renamed RXDX-108) a potent inhibitor of the [[kinase]] [[PKCiota]]
==Legal issues==
On June 25, 2010, Bayer sued Teva for falsely claiming that Gianvi, Teva's Generic of Yaz, was "stabilized by betadex as a [[clathrate]]."<ref name="Bayer Sues Teva and Barr for False Advertising"/> The lawsuit stems from Bayer's US patent, 5798338, on the binding and preservative agents that were not in fact present in Gianvi. "In the preparation of such low-dosed dosage forms, strong fluctuations of the active ingredient concentrations in the dosage units occur almost unavoidably (inadequate content uniformity), which manifest themselves more strongly, the smaller the amount of the active ingredient. It has now been found that the drawbacks that are observed especially in the preparation and storage of dosage forms which contain low-dosed steroidal sex hormones can be avoided, at least to a large extent, if dosage forms are prepared that contain powdery cyclodextrin clathrates of these active ingredients."<ref name="Solid dosage forms that contain clathrates"/>
The settlement of the lawsuit resulted in Teva changing its product marketing to remove the claim that it used the same ingredients as Yaz.<ref name="Gianvi Pharmacist Letter"/>{{Dead link|date=May 2011}} Bayer's patent is on a method specifically designed to prevent oxidative degradation of the estrogen.
In January 2015, the [[Supreme Court of the United States]] decided on the [[Copaxone]] patent in [[Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.]].<ref>{{cite web|title=Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.|url=http://www.scotusblog.com/case-files/cases/teva-pharmaceuticals-usa-inc-v-sandoz-inc/?wpmp_switcher=desktop|website=SCOTUSblog|accessdate=January 27, 2015}}</ref>
In December 2016, the [[State attorney general|attorneys general]] of 20 states filed a civil complaint accusing Teva Pharmaceutical of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged [[Price fixing|price collusion schemes]] between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.<ref>{{cite news |last=Thomas |first=Katie |url=https://www.nytimes.com/2016/12/15/business/generic-drug-price-lawsuit-teva-mylan.html |title=20 States Accuse Generic Drug Companies of Price Fixing |work=[[The New York Times]] |date=2016-12-15 |accessdate=2016-12-16 }}</ref>
==Subsidiaries==
===Africa===
*Assia Pharmaceuticals Ltd.
*Teva Pharmaceuticals (Pty) Ltd.
===Asia===
{{colbegin||22em}}
*Oncotest [Israel]
*Ratio Pharma
*TAPI Teva API Israel
*Teva API India Ltd.
*Teva Israel
*Teva Japan
*Teva Singapore
*Teva SLE [Israel]
{{colend}}
===Latin America===
{{colbegin||22em}}
*Ivax Argentina
*Laboratorio Chile
*Teva Brazil
*Teva Mexico
*Teva Perú (Corporación Medco and Infarmasa)
{{colend}}
===North America===
{{colbegin||22em}}
*Barr Pharmaceuticals
*Plantex USA
*Teva Animal Health
*Teva Biopharmaceuticals USA
*[[Teva Canada]]
*Teva Neuroscience
*Teva Neuroscience Canada
*Teva Parenteral Medicines
*Teva Pharmaceuticals Curaçao N.V.
*Teva Pharmaceuticals USA
*Teva Specialty Pharmaceuticals
{{colend}}
===Europe===
{{colbegin||22em}}
*Med Ilaç A.Ş.
*Plantex Chemicals B.V.
*Pliva Croatia
*Prosintex – ICI
*Ratiopharm GmbH
*Sicor Biotech UAB (Lithuania)
*Sicor Europe
*Sicor Italy S.r.I.
*Teva API International Spain
*Teva Belarus
*Teva Belgium
*Teva Bulgaria
*Teva Czech-Republic
*Teva Classics France
*Teva Finland Oy
*Teva Generics Spain
*Teva Group Germany
*Teva Hungary Ltd.
*Teva Kazakhstan
*Teva Moscow
*Teva Pharmaceuticals Europe B.V.
*Teva Pharmachemie B.V.
*Teva Pharma UK
*Teva Pharma AG
*Teva Italia S.r.l.
*Teva Pharma Portugal Ltd.
*Teva Serbia d.o.o.
*Teva Sweden AB
*Teva Pharmaceutical Fine Chemicals S.r.I.
*Teva Pharmaceutical Works Ltd.
*Teva Pharmaceuticals CR, s.r.o.
*Teva Pharmaceuticals Ireland
*Teva Pharmaceuticals Polska (Poland)
*Teva Pharmaceuticals Slovakia, s.r.o.
*Teva UK Limited
*Teva Ukraine
{{colend}}
==Pharmaceutical products==
{{Expand list|date=October 2016}}
{{Div col||20em}}
*[[Adderall]] ([[generic drug|generic]] and branded)
*[[Adrucil]]
*[[Alprazolam]]
*[[Amikacin]] [[Sulfate]]
*[[Amitriptyline]]
*[[Amoxicillin]]
*[[Apri]]
*[[Aripiprazole]] (generic)
*[[Atomoxetine]]
*[[Atorvastatin]]
*[[Augmentin]] (generic)
*[[Aviane]]
*[[Azathioprine]]
*[[Azithromycin]]
*[[Baclofen]]
*[[Balziva]]
*[[Bisoprolol|Bisoprolol Fumarate]]
*[[Bleomycin]]
*[[Budeprion]]
*[[Budesonide]]
*[[Buspirone]]
*[[Calcitriol]]
*[[Camrese]]
*[[Carboplatin]]
*[[Cefdinir]]
*[[Cephalexin]]
*[[Ciclosporin]]
*[[Ciprofloxacin]]
*[[Citalopram]]
*[[Cetirizine]]
*[[Isotretinoin|Claravis]]
*[[Clarithromycin]]
*[[Clonazepam]]
*[[Clozapine]]
*[[Codeine]]
*[[Copaxone]]
*[[Cryselle]]
*[[Cyclosporine]]
*[[Daunorubicin]]
*[[Dexmethylphenidate]]
*[[Dextroamphetamine]]
*[[Diazepam]]
*[[Dihydrocodeine]]
*[[Doxorubicin]] [[HCl]]
*[[Enpresse]]
*[[Epirubicin]] HCl
*[[Epoprostenol]] [[Sodium]]
*[[Errin]]
*[[Escitalopram]]
*[[Estazolam]]
*[[Estradiol]]
*[[Etodolac]]
*[[Famciclovir]]
*[[Filgrastim]]
*[[Fiorinal]]<ref>Mfg. by [[Watson Pharmaceuticals]]. See [[Actavis#Actavis Acquisition and Watson Name Change|Actavis Acquisition and Watson Name Change]], and [[Actavis#Allergan.2C inc Acquisition and Actavis.2C plc Name Change|Allergan, Inc. Acquisition and Actavis, plc Name Change]]</ref>
*[[Flunitrazepam]]
*[[Fluocinonide]]
*[[Fluconazole]]
*[[Fluoxetine]]
*[[Fluvoxamine]]
*[[Gabapentin]]
*[[Haloperidol]]
*Haloperidol [[Decanoate]]
*[[Ibuprofen Max]]
*[[Idarubicin]] HCl
*[[Ifosfamide]]
*[[Irinotecan]]
*[[Drospirenone|Gianvi]]
*[[Irbesartan]]
*[[Junel]]
*[[Kariva]]
*[[Kelnor]]
*[[Lamotrigine]]
*[[Laquinimod]]
*[[Letrozole]]
*[[Leucovorin]] [[Calcium]]
*[[Losartan]]
*[[Methotrexate]]
*[[Methylphenidate]]
*[[Mirtazapine]]
*[[Mitoxantrone]]
*[[Montelukast]] (generic) <ref>DeNoon, D. (August 3, 2012). Generic singulair approved. Retrieved from http://www.webmd.com/asthma/news/20120803/generic-singulair-approved</ref>
*[[Naltrexone]]
*[[Naproxen]]{{Citation needed|date=March 2014}}
*[[Norepinephrine (drug)|Norepinephrine]]
*[[Norethisterone]]
*[[Nortrel]]
*[[Nortriptyline]]
*[[Nuvigil]]
*[[Nystatin]]
*[[Ocella]]
*[[Olanzapine]]
*[[Omeprazole]]
*[[Optalgin]]
*[[Oxycodone]]
*[[Oxymorphone]]
*[[Pantoprazole]]<ref name=genericprotonixlaunch/>
*[[Phentermine]]
*Portia
*[[Pravastatin]]
*[[Prednisolone]]
*[[ProAir]]
*[[Provigil]]
*[[Quetiapine]]
*[[QVAR]]
*[[beclomethasone dipropionate|QNASL]]
*[[Ramipril]]
*[[Rasagiline]]
*[[Salbutamol|Salbutamol (Albuterol)]]
*[[Sertraline]]
*[[Simvastatin]]
*[[Ortho-Cyclen|Sprintec]]
*[[Sulfamethoxazole]] [[Trimethoprim]]
*[[Sumatriptan]]
*Tamoxifen
*[[Temazepam]]
*[[Temozolomide]]
*[[Terbinafin]]
*[[Topiramate]]
*[[Trazodone]]
*[[Ortho Tri-Cyclen|Tri-Sprintec]]
*[[Ursodiol]]
*[[Velivet]]
*[[Venlafaxine]]
*[[Warfarin]]
*[[Zolpidem]]
{{Div col end}}
==See also==
{{Portal|Companies}}
*[[Economy of Israel]]
*[[Science and technology in Israel]]
*[[Health care in Israel]]
*[[BioTime]]
*[[Teva Active Pharmaceutical Ingredients (TAPI)]]
*[[Qualitest]]
==References==
{{Reflist|2|refs=
<ref name="21st Century — Global Leadership">http://www.tevapharm.com/about/history.asp The History of Teva</ref>
<ref name="Bayer Sues Teva and Barr for False Advertising">
{{cite web
|title=Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Teva’s Generic Oral Contraceptive Gianvi
|url=http://pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room95.php
|author=Bayer HealthCare Pharmaceuticals Inc.
|date=June 25, 2010
|accessdate=December 26, 2010
|deadurl=yes
|archiveurl=https://web.archive.org/web/20110103015518/http://pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room95.php
|archivedate=January 3, 2011
|df=mdy
}}</ref>
<ref name="tevanr2002">
{{cite web
| title = Teva news release hiring Israel Makov
| url = http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle_Print&ID=1556547&highlight=
| author = Teva Pharmaceuticals Inc.
| date = February 14, 2002
| accessdate = September 28, 2014
}}</ref>
<ref name="ynet2006">
{{cite web
| title = Ynet reports Israel Makov resignation
| url = http://www.ynetnews.com/articles/1,7340,L-3316626,00.html
| author = Golan Hazani.
| date = October 18, 2006
| accessdate = September 28, 2014
}}</ref>
<ref name=biojerusalem>{{cite web
|url=http://www.biojerusalem.org.il/database_company.asp?ID=76
|title=Teva Pharmaceutical Industries—Jerusalem
|work=Database
|publisher=[[BioJerusalem]]
|location=Jerusalem, Israel
|archiveurl=https://web.archive.org/web/20110721143023/http://www.biojerusalem.org.il/database_company.asp?ID=76
|archivedate=July 21, 2011
|accessdate=
|deadurl=yes
|df=mdy
}}</ref>
<ref name=bloomberg2jan2012>{{Cite news | agency=Bloomberg News | date=January 2, 2012 |title=Teva Names a New Chief Executive | work=[[The New York Times]] | department=Business Day | url=https://www.nytimes.com/2012/01/03/business/teva-names-a-new-chief-executive.html | accessdate=January 3, 2012 | archivedate=April 27, 2012 | archiveurl=https://web.archive.org/web/20120427040309/http://www.nytimes.com/2012/01/03/business/teva-names-a-new-chief-executive.html }}{{registration required}}</ref>
<ref name=coren2008>{{Cite news | last=Coren | first=Ora | title=Most respected managers in market: Tshuva, Dankner, Maor and Hurvitz | work=[[Haaretz]] | accessdate=March 21, 2014 | date=February 21, 2008 | archivedate=October 20, 2012 | url=http://www.haaretz.com/print-edition/business/most-respected-managers-in-market-tshuva-dankner-maor-and-hurvitz-1.239727 | archiveurl=https://web.archive.org/web/20121020133703/http://www.haaretz.com/print-edition/business/most-respected-managers-in-market-tshuva-dankner-maor-and-hurvitz-1.239727 }}</ref>
<ref name=geneng20140215>{{cite news | title=People | date=February 15, 2014 | page=41 | work=[[Gen. Eng. Biotechnol. News]] | type=paper | volume=34 | issue=4 }}</ref>
<ref name=geneng20140215p10>{{cite news | title=Teva Outbids Endo, Acquires NuPathe for $144M+ | department=News: Industry Watch | type=paper | work=[[Gen. Eng. Biotechnol. News]] | page=10 | date=February 15, 2014 | volume=34 | issue=4 }}</ref>
<ref name=genericprotonixlaunch>{{cite web|url=http://www.tevapharm.com/pr/2007/pr_708.asp |title=Teva Announces Launch Of Generic Protonix Tablets |work=tevapharm.com |deadurl=yes |archiveurl=https://web.archive.org/web/20071229041600/http://www.tevapharm.com/pr/2007/pr_708.asp |archivedate=December 29, 2007 |df=mdy }}</ref>
<ref name="Gianvi Pharmacist Letter">{{cite web|title=Microsoft Word – Gianvi Pharmacist Letter – RevD – Final 7-1-10 – web versi... |author=Maureen M Cavanaugh, Teva Pharmaceuticals |url=http://www.tevausa.com/assets/base/products/Gianvi_Letter_7-1-10.pdf |date=July 1, 2010 |accessdate=December 26, 2010 |deadurl=yes |archiveurl=https://web.archive.org/web/20120314145028/http://www.tevausa.com/assets/base/products/Gianvi_Letter_7-1-10.pdf |archivedate=March 14, 2012 }}</ref>
<ref name=hollisfiercepharma2010>{{cite web
|url=http://www.fiercepharma.com/special-reports/top-10-generic-drug-companies-2010/teva-top-10-generic-drug-companies-2010
|title=Teva – Top 10 Generic Drug Companies 2010
|first=Liz Jones
|last=Hollis
|date=August 10, 2010
|work=FiercePharma
|publisher=[[FierceMarkets]]
|location=Washington, DC, United States
|accessdate=November 3, 2010
|archiveurl=http://www.webcitation.org/5yXPMLkBa?url=http://www.fiercepharma.com/special-reports/top-10-generic-drug-companies-2010/teva-top-10-generic-drug-companies-2010
|archivedate=May 8, 2011
|deadurl=yes
|df=mdy
}}</ref>
<ref name=KGPTM2011>{{cite news
|title=Teva plans $500 million Japan acquisition
|first=Kevin
|last=Grogan
|url=http://www.pharmatimes.com/Article/11-05-05/Teva_plans_500_million_Japan_acquisition_-_Nikkei.aspx
|newspaper=[[PharmaTimes Magazine]]
|location=London, England
|date=May 5, 2011
|at=Online PharmaTimes
|accessdate=May 7, 2011
|archiveurl=http://www.webcitation.org/5yVp5Pr7b?url=http://www.pharmatimes.com/Article/11-05-05/Teva_plans_500_million_Japan_acquisition_-_Nikkei.aspx
|archivedate=May 7, 2011
|deadurl=yes
|df=mdy
}}</ref>
<ref name=levinresig>
{{Cite news
|title=Teva CEO Jeremy Levin steps down
|work=Globes
|accessdate=October 30, 2013
|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000889846
|deadurl=yes
|archiveurl=https://web.archive.org/web/20131104152001/http://www.globes.co.il/serveen/globes/docview.asp?did=1000889846
|archivedate=November 4, 2013
|df=mdy
}}</ref>
<ref name=reuters20140109>{{cite news | title=Israel's Teva Pharm names Vigodman as CEO | agency=Reuters | url=http://www.reuters.com/article/2014/01/09/tevapharm-ceo-idUSL6N0KJ0LT20140109 | date=January 9, 2014 | deadurl=no | archivedate=January 9, 2014 | archiveurl=https://web.archive.org/web/20140109120239/http://www.reuters.com/article/2014/01/09/tevapharm-ceo-idUSL6N0KJ0LT20140109 }}</ref>
<ref name="Teva employees gain $222m on options">{{cite news|title=Teva employees gain $222m on options |first=Koby |last=Yeshayahou |url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000623808&fid=1725 |newspaper=[[Globes]] |publisher=[[Globes Publisher Itonut]] |location=Rishon Le-Zion, Israel |date=February 16, 2011 |at=globes-online.com |accessdate= |archiveurl=http://www.webcitation.org/5yXQENLt8?url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000623808&fid=1725 |archivedate=May 8, 2011 |deadurl=yes |df= }}</ref>
<ref name="Teva to Acquire Generics Firm">{{cite news|title=Teva to Acquire Generics Firm |author=Jonathan D. Rockoff |author2=Eyk Henning |url=https://online.wsj.com/article/SB10001424052748704207504575129240833529842.html |format=~100 words |newspaper=[[The Wall Street Journal]] |location=New York City |date=March 19, 2010 |at=WSJ.com |accessdate=May 8, 2011 |archiveurl=http://www.webcitation.org/5yXX2YMH8?url=https://online.wsj.com/article/SB10001424052748704207504575129240833529842.html |archivedate=May 9, 2011 |deadurl=yes |df=mdy }}</ref>
<ref name=reuters>{{Cite news | title=Teva Pharmaceutical Industries Ltd (TEVA.O) Officers | publisher=Reuters | accessdate=October 11, 2008 | archivedate=September 29, 2008 | url=http://www.reuters.com/finance/stocks/officerProfile?symbol=TEVA.O&officerId=132712 | archiveurl=https://web.archive.org/web/20080929214726/http://www.reuters.com/finance/stocks/officerProfile?symbol=TEVA.O&officerId=132712 }}</ref>
<ref name=singernyt2010>{{cite news |first=Natasha |last=Singer |date=March 18, 2010
|url=https://www.nytimes.com/2010/03/19/business/global/19drugs.html |accessdate=March 18, 2010
|title=Teva to Acquire Top German Generics Maker for $5 Billion |newspaper=[[The New York Times]] }}</ref>
<ref name="Teva Completes Acquisition of Barr">{{cite web|url=http://www.tevapharm.com/pr/2008/pr_813.asp |title=Teva Completes Acquisition of Barr |work=tevapharm.com |deadurl=yes |archiveurl=https://web.archive.org/web/20090124234703/http://tevapharm.com/pr/2008/pr_813.asp |archivedate=January 24, 2009 |df=mdy }}</ref>
<ref name="Teva to acquire Ratiopharm in deal valued near $5 billion">{{cite web|url=http://www.marketwatch.com/story/teva-near-478-bln-deal-for-ratiopharm-reports-2010-03-18 |title=Teva to acquire Ratiopharm in deal valued near $5 billion |author=Robert Daniel |author2=Polya Lesova |date=March 18, 2010 |work=[[MarketWatch]] |publisher=[[Dow Jones & Co.]] |location=New York City |archiveurl=http://www.webcitation.org/5yXXk8ZU2?url=http://www.marketwatch.com/story/teva-near-478-bln-deal-for-ratiopharm-reports-2010-03-18 |archivedate=May 9, 2011 |accessdate=May 8, 2011 |deadurl=yes |df=mdy }}</ref>
<ref name="Teva to Buy Cephalon for $6.8 Billion">{{cite news| url=https://dealbook.nytimes.com/2011/05/02/teva-to-buy-cephalon-for-6-8-billion/?partner=rss&emc=rss | work=The New York Times | first=Chris V. | last=Nicholson | title=Teva to Buy Cephalon for $6.8 Billion | date=May 2, 2011}}</ref>
<ref name="Teva won't make more of powerful sedative">{{cite web | title = Teva won't make more of powerful sedative | url = http://www.msnbc.msn.com/id/37403276/ns/health-health_care/}}</ref>
<ref name="Solid dosage forms that contain clathrates">
{{cite web
|title=Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol
|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5798338.PN.&OS=PN/5798338&RS=PN/5798338
|archive-url=https://web.archive.org/web/20161220070617/http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5798338.PN.&OS=PN%2F5798338&RS=PN%2F5798338
|dead-url=yes
|archive-date=December 20, 2016
|author=Backensfeld
|date=August 25, 1998
|accessdate=December 26, 2010
|display-authors=etal
|df=
}}</ref>
<ref name="Yahoo deadlink">[https://news.yahoo.com/s/nm/20100318/bs_nm/us_ratiopharm Ratiopharm] {{dead link|date=June 2016|bot=medic}}{{cbignore|bot=medic}}</ref>
<ref name=yanairesign>
{{Cite news
| title = Teva CEO Shlomo Yanai leaving in May, to be replaced by American
| work = Haaretz
| accessdate = December 7, 2013
| url = http://www.haaretz.com/business/teva-ceo-shlomo-yanai-leaving-in-may-to-be-replaced-by-american-1.405070
}}
</ref>
}}
==External links==
{{Commons category}}
*[http://www.tevapharm.com/ Teva Pharmaceutical Industries Official website]
*[http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272006/354138/article.pdf Pharmaceutical Executive] (PDF)
*{{cite web |url=http://www.tevausa.com/default.aspx?pageid=75
|title=Recent Product Launches, Teva Pharmaceuticals USA |accessdate=February 21, 2008 }}<!-- Strange entry, reported to Ceyockey's talk page 2014-03-12 -->
*[http://articles.economictimes.indiatimes.com/2012-01-03/news/30584630_1_teva-pharmaceutical-industries-shlomo-yanai-cephalon The Economic Times]
{{TA 25 companies}}
[[Category:Companies listed on TASE]]
[[Category:Companies listed on the New York Stock Exchange]]
[[Category:Pharmaceutical companies of Israel]]
[[Category:Pharmaceutical companies established in 1901]]
[[Category:Science and technology in Israel]]
[[Category:Companies formerly listed on NASDAQ]]
[[Category:Generic drug manufacturers]]
[[Category:Israeli brands]]
[[Category:Economy of Jerusalem]]
[[Category:Life sciences industry]]
[[Category:Companies based in Petah Tikva]]
[[Category:Multinational companies headquartered in Israel]]All content in the above text box is licensed under the Creative Commons Attribution-ShareAlike license Version 4 and was originally sourced from https://de.wikipedia.org/w/index.php?oldid=166807086.
  This site is not affiliated with or endorsed in any way by the Wikimedia Foundation or any of its affiliates. In fact, we fucking despise them.
|